Pmv Pharmaceuticals Inc
$ 1.12
5.66%
25 Feb - close price
- Market Cap 56,404,000 USD
- Current Price $ 1.12
- High / Low $ 1.15 / 1.06
- Stock P/E N/A
- Book Value 2.28
- EPS -1.59
- Next Earning Report 2026-03-02
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.32 %
- ROE -0.52 %
- 52 Week High 1.84
- 52 Week Low 0.81
About
PMV Pharmaceuticals, Inc., a precision oncology company, is dedicated to the discovery and development of small molecule tumor agnostic therapies for p53 mutations in cancer. The company is headquartered in Cranbury, New Jersey.
Analyst Target Price
$7.60
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-12 | 2025-08-07 | 2025-05-07 | 2025-02-26 | 2024-11-07 | 2024-08-08 | 2024-05-09 | 2024-02-29 | 2023-11-09 | 2023-08-09 | 2023-05-10 | 2023-03-01 |
| Reported EPS | -0.4 | -0.41 | -0.34 | -0.45 | -0.37 | -0.02 | -0.3 | -0.31 | -0.34 | -0.38 | -0.42 | -0.43 |
| Estimated EPS | -0.4 | -0.39 | -0.3833 | -0.38 | -0.35 | -0.35 | -0.36 | -0.39 | -0.45 | -0.47 | -0.46 | -0.44 |
| Surprise | 0 | -0.02 | 0.0433 | -0.07 | -0.02 | 0.33 | 0.06 | 0.08 | 0.11 | 0.09 | 0.04 | 0.01 |
| Surprise Percentage | 0% | -5.1282% | 11.2966% | -18.4211% | -5.7143% | 94.2857% | 16.6667% | 20.5128% | 24.4444% | 19.1489% | 8.6957% | 2.2727% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-03-02 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -0.4 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: PMVP
2026-02-19 07:57:37
PMV Pharmaceuticals (NASDAQ:PMVP) saw its shares trade up 0.9% on Wednesday, reaching approximately $1.07-$1.09 on very light trading volume. The company, a precision oncology firm developing therapies for p53 mutations, has a market capitalization of $56.9 million. Analysts currently have a "Hold" rating on the stock with a consensus price target of $5.00, though coverage is split between buy and sell ratings.
2026-02-03 17:29:14
PMV Pharmaceuticals is preparing for a pivotal first quarter of 2026, with significant events anticipated for its lead cancer therapy program. The company plans to release quarterly financial results between February 27 and March 2, followed by a presentation at the 46th Annual TD Cowen Health Care Conference on March 2. A critical milestone is the targeted completion of patient enrollment for its platinum-resistant ovarian cancer study by the end of March, which is essential for its planned New Drug Application submission by Q1 2027.
2026-02-02 20:32:04
PMV Pharmaceuticals is entering a crucial first quarter of 2026 with several key events for its lead cancer therapy, rezatapopt. Investors are focused on upcoming financial results, a presentation at the TD Cowen Health Care Conference, and the critical completion of patient enrollment for its platinum-resistant ovarian cancer study. Meeting the enrollment target by late March 2026 is essential for the company's planned New Drug Application submission by Q1 2027.
2026-02-02 02:33:31
Analysts are showing bullish sentiment towards Palvella Therapeutics (PVLA) and Xeris Pharmaceuticals (XERS) in the Healthcare sector. Craig-Hallum analysts maintained Buy ratings for both companies, with significant upsides projected. Palvella Therapeutics has a Strong Buy consensus rating with an average price target of $182.15, while Xeris Pharmaceuticals also holds a Strong Buy consensus with an $11.00 average price target.
2026-01-29 07:58:12
PMV Pharmaceuticals (NASDAQ:PMVP) currently has a cash runway of about 21 months based on its US$129 million cash balance and a cash burn of US$73 million. The company's cash burn increased significantly by 54% over the last year, and its cash burn of US$73 million represents 117% of its US$62 million market capitalization, indicating a high risk of funding distress and potential shareholder dilution if it needs to raise more capital. Investors should be cautious given the accelerated cash burn relative to its market cap.
2026-01-29 07:30:58
PMV Pharmaceuticals (NASDAQ:PMVP) saw its shares increase by 3.4% on Tuesday, trading as high as $1.2450 and closing at $1.21. The trading volume was 40% above average, with approximately 352,182 shares changing hands. The company, focused on precision oncology, has a consensus "Hold" rating and a $5.00 price target from analysts, though Weiss Ratings reiterated a "sell."
